HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Veterinary Medicine / Faculty of Veterinary Medicine >
Japanese Journal of Veterinary Research >
Volume 65 Number 1 >

Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines

Files in This Item:
65-1_017-028.pdf2.59 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines
Authors: Ong, Siew Mei Browse this author
Yamamoto, Hiroki Browse this author
Saeki, Kohei Browse this author
Tanaka, Yuiko Browse this author
Yoshitake, Ryohei Browse this author
Nishimura, Ryohei Browse this author →KAKEN DB
Nakagawa, Takayuki Browse this author →KAKEN DB
Keywords: Topoisomerase inhibitors
canine osteosarcoma
canine mammary gland tumour
canine malignant melanoma
multi-drug resistant factors
Issue Date: Feb-2017
Publisher: Graduate School of Veterinary Medicine, Hokkaido University
Journal Title: Japanese Journal of Veterinary Research
Volume: 65
Issue: 1
Start Page: 17
End Page: 28
Abstract: Numerous topoisomerase inhibitors with proven efficacy have been used extensively to treat various human neoplasms. However, among these, only doxorubicin has been used and studied extensively in veterinary oncology. The current study was performed to evaluate the responsiveness of canine osteosarcoma (cOSA), mammary gland tumour (cMGT), and malignant melanoma (cMM) cell lines to several topoisomerase inhibitors. In addition, the correlation between the sensitivity to treatment and multi-drug resistant (MDR) factors was investigated. cOSA cell lines exhibited higher sensitivity than cMGT and cMM cell lines to all the topoisomerase inhibitors tested in vitro; this was associated with the levels of multi-drug resistance protein 1 (MDR1) gene expression in the cOSA cell lines. Treatment of cOSA (HMPOS) and cMGT cell line (CHMp) xenograft mouse models with etoposide markedly delayed tumour progression in HMPOS xenografts, but failed to elicit lasting anti-tumour effects on CHMp xenograft mice. The present findings suggest that MDR1 represents a molecular signature for prediction of treatment efficacy of topoisomerase inhibitors, especially that of etoposide, which may be a clinically useful anti-tumour agent for cOSA; however, further study is necessary to refine the treatment protocol.
Type: bulletin (article)
Appears in Collections:Japanese Journal of Veterinary Research > Volume 65 Number 1

Submitter: 獣医学部図書室

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University